UY33930A - Inhibidores novedosos de quinasas - Google Patents

Inhibidores novedosos de quinasas

Info

Publication number
UY33930A
UY33930A UY0001033930A UY33930A UY33930A UY 33930 A UY33930 A UY 33930A UY 0001033930 A UY0001033930 A UY 0001033930A UY 33930 A UY33930 A UY 33930A UY 33930 A UY33930 A UY 33930A
Authority
UY
Uruguay
Prior art keywords
new
quinase
inhibitors
quinase inhibitors
página
Prior art date
Application number
UY0001033930A
Other languages
English (en)
Inventor
Burger Matthew
Nishiguchi Gisele
Rico Alice
Robert Lowell Simmons
Aaron R Smith
Victoriano Tamez Jr
Tanner Huw
Wan Lifeng
Timothy D Machajewsky
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of UY33930A publication Critical patent/UY33930A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La invención proporciona compuestos de la Fórmula I, y compuestos relacionados como se describe adicionalmente en la presente, y composiciones farmacéuticas que comprenden estos compuestos. La invención proporciona además métodos para utilizar estos compuestos y composiciones para el tratamiento de trastornos asociados con niveles no deseados de la actividad de la PIM quinasa, incluyendo cánceres y trastornos autoinmunes.
UY0001033930A 2011-03-04 2012-03-01 Inhibidores novedosos de quinasas UY33930A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161449229P 2011-03-04 2011-03-04
US201161480015P 2011-04-28 2011-04-28

Publications (1)

Publication Number Publication Date
UY33930A true UY33930A (es) 2012-10-31

Family

ID=45873194

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033930A UY33930A (es) 2011-03-04 2012-03-01 Inhibidores novedosos de quinasas

Country Status (8)

Country Link
US (1) US20120225062A1 (es)
EP (1) EP2681195A1 (es)
JP (1) JP2014506917A (es)
CN (1) CN103402984A (es)
AR (1) AR085602A1 (es)
TW (1) TW201240986A (es)
UY (1) UY33930A (es)
WO (1) WO2012120428A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009009304A (es) * 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
EP2861585B1 (en) * 2012-05-21 2019-01-09 Novartis AG Novel ring-substituted n-pyridinyl amides as kinase inhibitors
ES2690829T3 (es) 2012-09-17 2018-11-22 Agios Pharmaceuticals, Inc. Uso de e-cadherina y vimentina para la selección de pacientes que responden al tratamiento
US9328106B2 (en) 2012-09-26 2016-05-03 Genentech, Inc. Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
KR20150085078A (ko) 2012-11-21 2015-07-22 아지오스 파마슈티컬스 아이엔씨. 글루타마제 억제제 및 사용 방법
WO2014079011A1 (en) 2012-11-22 2014-05-30 Agios Pharmaceuticals, Inc. Heterocyclic compounds for inhibiting glutaminase and their methods of use
US20150336960A1 (en) 2012-12-19 2015-11-26 Novartis Ag Aryl-substituted fused bicyclic pyridazine compounds
US9278950B2 (en) 2013-01-14 2016-03-08 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
BR122019024759B1 (pt) * 2013-01-15 2022-02-08 Incyte Holdings Corporation Compostos de tiazolacarboxamidas e piridinacarboxamida, composição compreendendo os mesmos, método de inibição da enzima pim1, pim2, ou pim3, e usos dos referidos compostos
JP2016528298A (ja) 2013-08-23 2016-09-15 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Ｐｉｍキナーゼ阻害剤として有用なフロピリジン及びチエノピリジンカルボキシアミド化合物
EP3119775B1 (en) 2014-03-18 2019-11-06 F. Hoffmann-La Roche AG Oxepan-2-yl-pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use
MX2016012244A (es) * 2014-03-21 2017-05-08 Agios Pharmaceuticals Inc Compuestos y sus metodos de uso.
WO2016010897A1 (en) 2014-07-14 2016-01-21 Incyte Corporation Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en) 2014-07-14 2017-02-28 Incyte Corporation Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US9540347B2 (en) 2015-05-29 2017-01-10 Incyte Corporation Pyridineamine compounds useful as Pim kinase inhibitors
TWI734699B (zh) 2015-09-09 2021-08-01 美商英塞特公司 Ｐｉｍ激酶抑制劑之鹽
US9920032B2 (en) 2015-10-02 2018-03-20 Incyte Corporation Heterocyclic compounds useful as pim kinase inhibitors
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE517868T1 (de) 2006-08-16 2011-08-15 Boehringer Ingelheim Int Pyrazinverbindungen, ihre verwendung und herstellungsverfahren
MX2009009304A (es) 2007-03-01 2009-11-18 Novartis Ag Inhibidores de cinasa pim y metodos para su uso.
US8293747B2 (en) * 2007-07-19 2012-10-23 Merck Sharp & Dohme Corp. Heterocyclic amide compounds as protein kinase inhibitors
AR070531A1 (es) * 2008-03-03 2010-04-14 Novartis Ag Inhibidores de cinasa pim y metodos para su uso
CN104311480A (zh) * 2008-09-02 2015-01-28 诺华股份有限公司 作为激酶抑制剂的吡啶甲酰胺衍生物
US20130109682A1 (en) * 2010-07-06 2013-05-02 Novartis Ag Cyclic ether compounds useful as kinase inhibitors

Also Published As

Publication number Publication date
TW201240986A (en) 2012-10-16
CN103402984A (zh) 2013-11-20
US20120225062A1 (en) 2012-09-06
AR085602A1 (es) 2013-10-16
EP2681195A1 (en) 2014-01-08
JP2014506917A (ja) 2014-03-20
WO2012120428A1 (en) 2012-09-13

Similar Documents

Publication Publication Date Title
UY33958A (es) Inhibidores de la glucosilceramida sintasa
UY33930A (es) Inhibidores novedosos de quinasas
CR20140024A (es) Compuestos inhibidores de metaloenzimas
CO7020912A2 (es) Inhibidores de bromodominios
UY34092A (es) Nuevos compuestos como inhibidores de jak
CO7111289A2 (es) Compuestos inhibidores de metaloenzimas
UY34365A (es) Compuestos heterociclicos
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
UY33925A (es) Inhibidores tricíclicos de quinasas
UY34550A (es) Bencilpirazoles sustituidos
UY34206A (es) Anticuerpo monoclonal de interleucina-31
UY34145A (es) Compuestos inhibidores de metaloenzimas
CO7091177A2 (es) Inhibidores de la beta-secretasa
UY34004A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO[2,3-d]PIRIMIDINA TROPOMIOSINA
UY34156A (es) Compuestos inhibidores de metaloenzimas
UY34374A (es) Benzilindazoles sustituidos
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
UY34027A (es) Inhibidores sustituidos de acetil-coa carboxilasa.
UY34523A (es) Derivados de betulina
CR20130539A (es) Triazolopiridinas
UY34006A (es) Imidazopiridazinas
BR112014003027A2 (pt) formulação herbicida melhorada
UY34442A (es) 2-tiopirimidinonas.
UY34158A (es) Composicion herbicida
UY4153Q (es) Batería

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201019